Eli Lilly Surpasses Q4 Estimates, Boosts Full-Year Guidance, and Confirms April 9 Obesity Drug Rollout
LLY sits 53% above its 52-week low of $623.78.
Summary
Eli Lilly reported robust Q4 2023 revenue of $19.29 billion, marking a significant 42.6% year-over-year increase and comfortably surpassing analyst estimates by 7.4%. This strong financial performance was complemented by the company raising its full-year revenue guidance, signaling continued confidence in its growth trajectory. A key operational update includes the confirmation that Eli Lilly's new obesity treatment, Foundayo, will begin stocking in U.S. retail pharmacies from April 9, following its recent FDA approval. This firm distribution date is a critical next step in the market penetration of a product expected to be a major growth driver. However, the company also noted a decline in March Mounjaro sales in India, attributing it to pricing dynamics and generic competition in that specific market. Additionally, a study identified gene variants linked to higher nausea and vomiting risk with tirzepatide (Mounjaro/Zepbound), which could subtly influence patient perception and prescribing patterns. Traders will closely monitor Foundayo's initial adoption rates and sales, alongside the evolving competitive landscape for GLP-1 drugs.
At the time of this announcement, LLY was trading at $955.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $902.5B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.